Santhera Pharmaceuticals’ Post

Santhera Pharmaceuticals reposted this

View organization page for Santhera Pharmaceuticals, graphic

16,970 followers

Today, Santhera announced financing taking the Company to cash flow break-even! – “We are very pleased to have achieved significant financing goals for Santhera and our shareholders through these initiatives. The new financing is non-dilutive to shareholders, the royalty monetization is partial and capped, leaving upside potential to Santhera, and the debt repayment schedule aligns well with our growth expectations,” said Andrew Smith, Chief Financial Officer of Santhera. “Importantly, it addresses our near-term debt obligations and provides us with sufficient funding to drive market launches and growth of AGAMREE in Europe and to pursue additional development programs for AGAMREE.” Read our press release at https://bit.ly/3Rx4Qpg #Santhera #theirfutureourfocus

  • No alternative text description for this image
Khan Ozol, PhD

Founder and CEO at PharmaTalent Inc. - serving Life Science companies to optimise their Global Executive Recruitment, Talent Scouting, and Management strategies.

4mo

Well done and congratulations! 👍 Significant milestone reached ✅

Massimo Radaelli

President & CEO presso Noventia Pharma

4mo

Congratulations David and Santhera Team for these important financial results

Thomas Meier, Dr.

Managing Partner at Viopas Venture Consulting GmbH

4mo

Excellent achievement Andrew!

Kosta Mitrofansky

Healthcare Technology Executive, Entrepreneur, IT Expert & Angel Investor

4mo

That's fantastic news! 👍

Like
Reply
Hervé SIENDT, PhD, PMP

Senior Scientist in Medicinal Chemistry - Looking for new role in Pharma Industry

4mo

Congratulation to the whole Santhera Team ! Really great news indeed.

Reinhard Karge

Founder, President and Chief Executive

4mo

Congratulations to Santharam! 👍

Raffaella Willmann

Research manager at the Swiss Foundation for Research on Muscle Diseases

4mo

Congratulations Santhera Pharmaceuticals !!

See more comments

To view or add a comment, sign in

Explore topics